Table 3 Onabotulinumtoxin A (OBT-A) in the context of other prophylactic therapies for chronic migraine and timing of OBT-A initiation
Answer options | n (%) |
|---|---|
Frequency of combination of OBT-A with other prophylactic therapies | |
Never | 3 (4.8) |
Rarely | 14 (22.2) |
Frequently | 45 (71.4) |
Always | 1 (1.6) |
Number of prophylactic therapies used before initiating OBT-A | |
0 | 1 (1.6) |
1 | 2 (3.2) |
2-3 | 22 (34.9) |
> 3 | 38 (60.3) |
Rating of tolerability profile of OBT-A vs. oral prophylactic therapies | |
More favorable | 57 (90.5) |
Comparable | 5 (7.9) |
Less favorable | 1 (1.6) |
Rating of efficacy/safety ratio of OBT-A vs. oral prophylactic therapies | |
More favorable | 44 (69.8) |
Comparable | 18 (28.6) |
Less favorable | 1 (1.6) |
Impression of greater efficacy of OBT-A when initiated early in the course of chronic migraine | |
Never | 0 |
Rarely | 9 (14.3) |
Frequently | 51 (80.9) |
Always | 3 (4.8) |
Recommendation of OBT-A as first-line treatment based on the pharmacological profile | |
Yes | 30 (47.6) |
No | 33 (52.4) |